Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Colorectal Adenocarcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Colorectal Cancer (1218)

Colon Cancer (151)

Rectal Cancer (65)

Colorectal Cancer (1218)

Colon Cancer (151)

Rectal Cancer (65)

›

MSI-H/dMMR	Colorectal Adenocarcinoma	MSI-H/dMMR	Colorectal Adenocarcinoma	nivolumab + ipilimumab Sensitive: C1 - Off-label nivolumab + ipilimumab Sensitive : C1	nivolumab + ipilimumab Sensitive: C1 - Off-label nivolumab + ipilimumab Sensitive : C1
PIK3CA V955G	Colorectal Adenocarcinoma	PIK3CA V955G	Colorectal Adenocarcinoma	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
ALK fusion	Colorectal Adenocarcinoma	ALK fusion	Colorectal Adenocarcinoma	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
KRAS mutation	Colorectal Adenocarcinoma	KRAS mutation	Colorectal Adenocarcinoma	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3
EWSR1 mutation	Colorectal Adenocarcinoma	EWSR1 mutation	Colorectal Adenocarcinoma	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
PD-L2 overexpression	Colorectal Adenocarcinoma	PD-L2 overexpression	Colorectal Adenocarcinoma	PD-L1 inhibitor + PD-L2 inhibitor Sensitive: D – Preclinical PD-L1 inhibitor + PD-L2 inhibitor Sensitive : D	PD-L1 inhibitor + PD-L2 inhibitor Sensitive: D – Preclinical PD-L1 inhibitor + PD-L2 inhibitor Sensitive : D
KRAS G13D	Colorectal Adenocarcinoma	KRAS G13D	Colorectal Adenocarcinoma	ASN007 Sensitive: D – Preclinical ASN007 Sensitive : D	ASN007 Sensitive: D – Preclinical ASN007 Sensitive : D
APC mutation	Colorectal Adenocarcinoma	APC mutation	Colorectal Adenocarcinoma	ST316 Sensitive: D – Preclinical ST316 Sensitive : D	ST316 Sensitive: D – Preclinical ST316 Sensitive : D